Literature DB >> 18029108

Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience.

Daniel R Gomez1, Bradford S Hoppe, Suzanne L Wolden, Joanne E Zhung, Snehal G Patel, Dennis H Kraus, Jatin P Shah, Ronald A Ghossein, Nancy Y Lee.   

Abstract

PURPOSE: To analyze the recent experience of patients with adenoid cystic carcinoma treated with radiation therapy at Memorial Sloan-Kettering Cancer Center. METHODS AND MATERIALS: From 1990 to 2004, a total of 59 patients with a diagnosis of primary adenoid cystic carcinoma of the head and neck received radiation therapy at our institution. The subsite distribution was oral cavity, 28% (n = 17); paranasal sinuses, 22% (n = 13); parotid, 14% (n = 8); submandibular, 14% (n = 8); oropharynx, 10% (n = 6); sublingual, 3% (n = 2); nasopharynx, 3% (n = 2); and other, 5% (n = 3). T Stage distribution was T1, 34% (n = 20); T2, 19% (n = 11); T3, 14% (n = 8); and T4, 34% (n = 20). Twenty-nine percent of patients (n = 17) were treated with intensity-modulated radiation therapy; 25% (n =15), with three-dimensional conformal therapy, and the remainder, with conventional techniques. Ninety percent (n = 53) of patients received treatment including the base of skull.
RESULTS: Median follow-up for surviving patients was 5.9 years. Five-year and 10-year rates of local control and distant metastases-free survival were 91%/81% and 81%/49%, respectively. Five-year and 10-year rates of disease-free and overall survival were 76%/40% and 87%/65%, respectively. On univariate analysis, stage T4 (p = 0.004) and gross/clinical nerve involvement (p = 0.002) were associated with decreased progression free survival, whereas stage T4 and lymph node involvement were associated with decreased overall survival (p = 0.046 and p < 0.001, respectively).
CONCLUSIONS: Radiation therapy in combination with surgery produces excellent rates of local control, although distant metastases account for a high proportion of failures. Routine treatment to the base of skull reduces the significance of histologic perineural invasion, but major nerve involvement remains an adverse prognostic factor.

Entities:  

Mesh:

Year:  2007        PMID: 18029108     DOI: 10.1016/j.ijrobp.2007.08.008

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.

Authors:  Monali Swain; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Roshan Patil; Vedang Murthy; Tejpal Gupta; Naveen Mummudi; Kumar Prabhash; Amit Joshi; Vijay Maruti Patil; Vanita Naronha; Jai Prakash Agarwal
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-09       Impact factor: 2.503

2.  Clinicopathological review and survival characteristics of adenoid cystic carcinoma.

Authors:  Fariba Binesh; Ali Akhavan; Omid Masumi; Abbas Mirvakili; Nasim Behniafard
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-05

3.  Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Amit Bahl; Naresh Kumar Panda; Arun Elangovan; Jaimanti Bakshi; Roshan Verma; Satyawati Mohindra; Rijuneeta Gupta; Arun Singh Oinam; Satinder Kaur; R K Vashishta; Sushmita Ghoshal
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-07-07

Review 4.  Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review.

Authors:  Carlos Suárez; Leon Barnes; Carl E Silver; Juan P Rodrigo; Jatin P Shah; Asterios Triantafyllou; Alessandra Rinaldo; Antonio Cardesa; Karen T Pitman; Luiz P Kowalski; K Thomas Robbins; Henrik Hellquist; Jesus E Medina; Remco de Bree; Robert P Takes; Andrés Coca-Pelaz; Patrick J Bradley; Douglas R Gnepp; Afshin Teymoortash; Primož Strojan; William M Mendenhall; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Marc Hamoir; Pieter J Slootweg; Vincent Vander Poorten; Michelle D Williams; Bruce M Wenig; Alena Skálová; Alfio Ferlito
Journal:  Auris Nasus Larynx       Date:  2016-03-24       Impact factor: 1.863

5.  Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck.

Authors:  Teruhito Aihara; Norimasa Morita; Nobuhiko Kamitani; Hiroaki Kumada; Koji Ono; Junichi Hiratsuka; Tamotu Harada
Journal:  Int J Clin Oncol       Date:  2013-06-25       Impact factor: 3.402

6.  Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation.

Authors:  Safina Ali; Frank L Palmer; Nora Katabi; Nancy Lee; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Laryngoscope       Date:  2017-03-21       Impact factor: 3.325

7.  Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.

Authors:  Jin Fang; Yang-Yang Bao; Shui-Hong Zhou; Xing-Mei Luo; Hong-Tian Yao; Jian-Feng He; Qin-Ying Wang
Journal:  Oncol Lett       Date:  2012-09-05       Impact factor: 2.967

8.  Radiation therapy in the treatment of minor salivary gland tumors.

Authors:  Lucas R Salgado; Daniel E Spratt; Nadeem Riaz; Paul B Romesser; Suzanne Wolden; Shyam Rao; Christine Chin; Julian C Hong; Richard Wong; Nancy Y Lee
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

Review 9.  Perineural Spread in Noncutaneous Head and Neck Cancer: New Insights into an Old Problem.

Authors:  Moran Amit; Ayelet Eran; Salem Billan; Eran Fridman; Shorook Na'ara; Tomer Charas; Ziv Gil
Journal:  J Neurol Surg B Skull Base       Date:  2016-02-26

Review 10.  18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.

Authors:  Eric C Ford; Joseph Herman; Ellen Yorke; Richard L Wahl
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.